| 163.48 11.88 (7.84%) | 11-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 200.49 |
1-year : | 234.18 |
| Resists | First : | 171.66 |
Second : | 200.49 |
| Pivot price | 157.61 |
|||
| Supports | First : | 156.19 |
Second : | 146.63 |
| MAs | MA(5) : | 160.64 |
MA(20) : | 156.72 |
| MA(100) : | 128.65 |
MA(250) : | 109.61 |
|
| MACD | MACD : | 4 |
Signal : | 4.6  |
| %K %D | K(14,3) : | 39.7 |
D(3) : | 51.8 |
| RSI | RSI(14): 60.5 |
|||
| 52-week | High : | 171.66 | Low : | 81.13 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RVTY ] has closed below upper band by 19.1%. Bollinger Bands are 20.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 171.75 - 172.59 | 172.59 - 173.45 |
| Low: | 160.6 - 161.45 | 161.45 - 162.31 |
| Close: | 162.12 - 163.46 | 163.46 - 164.82 |
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
Wed, 04 Nov 2026
Revvity Q3 Earnings Call Highlights - Yahoo Finance
Tue, 03 Nov 2026
Revvity Inc (RVTY) (Q3 2026) Earnings Call Highlights: Strong Organic Growth and Raised ... - Yahoo Finance
Tue, 03 Nov 2026
Revvity (RVTY) Q3 2026 Earnings Call Transcript - شبكة تواصل الإخبارية
Tue, 03 Nov 2026
Revvity climbs 8% after Q3 results and raised guidance (RVTY:NYSE) - Seeking Alpha
Tue, 03 Nov 2026
Revvity Edges Past Q3 2026 Estimates, Posts $1.38 EPS, Revenue Up 4% - AlphaStreet
Tue, 03 Nov 2026
Revvity third quarter 2026 revenue rises to $729 million - grafa.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 112 (M) |
| Shares Float | 102 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 104 (%) |
| Shares Short | 6,300 (K) |
| Shares Short P.Month | 6,310 (K) |
| EPS | 2.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 64.77 |
| Profit Margin | 8.1 % |
| Operating Margin | 17 % |
| Return on Assets (ttm) | 2.3 % |
| Return on Equity (ttm) | 3.2 % |
| Qtrly Rev. Growth | 1.2 % |
| Gross Profit (p.s.) | 14.33 |
| Sales Per Share | 26.07 |
| EBITDA (p.s.) | 7.84 |
| Qtrly Earnings Growth | 1.2 % |
| Operating Cash Flow | 628 (M) |
| Levered Free Cash Flow | 605 (M) |
| PE Ratio | 78.22 |
| PEG Ratio | 0.7 |
| Price to Book value | 2.52 |
| Price to Sales | 6.26 |
| Price to Cash Flow | 29.06 |
| Dividend | 0.07 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|